After a 3-year follow-up time, they found that XO activity was an independent predictor of CV events in CKD and HD patients, regardless of uric acid levels, thus suggesting that the beneficial effects observed with XO inhibitors on CVD in CKD may be due to the reduction of OS [79]. The gene discussed is XDH; the disease is chronic kidney disease.